Reuters logo
BRIEF-Trillium announces private placement to fund development of cancer drugs
November 15, 2017 / 2:24 PM / a month ago

BRIEF-Trillium announces private placement to fund development of cancer drugs

Nov 15 (Reuters) - Trillium Therapeutics Inc-

* Trillium announces private placement

* Trillium Therapeutics - ‍entered into subscription agreements for sale of 1.95 million shares & 400,000 Series II non-voting convertible first preferred shares​

* Trillium Therapeutics - ‍net proceeds from private placement will be used to continue development of TTI-621 in hematologic cancers and solid tumors​

* Trillium Therapeutics Inc - ‍subscription agreements for offering at a price of U.S.$8.50 per share Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below